Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-11-01 5:01 pm Sale |
2022-10-20 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-5,424,009 (Position Closed) |
Filing History |
| 2022-10-20 4:05 pm Sale |
2022-10-16 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
HIRSCHMAN ORIN | 975,993 2.800% |
-1,735,377 (-64.00%) |
Filing History |
| 2022-02-11 3:32 pm Purchase |
2021-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
HIRSCHMAN ORIN | 2,711,370 7.900% |
669,559 (+32.79%) |
Filing History |
| 2021-09-14 6:11 pm Purchase |
2021-09-03 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
HIRSCHMAN ORIN | 2,041,811 5.940% |
2,041,811 (New Position) |
Filing History |
| 2021-04-09 6:02 pm Purchase |
2021-03-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
BLACKROCK INC BLK |
1,605,160 4.800% |
36,805 (+2.35%) |
Filing History |
| 2021-02-16 3:07 pm Sale |
2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Cormorant Asset Management LP | 0 0.000% |
-1,350,000 (Position Closed) |
Filing History |
| 2021-02-12 12:39 pm Sale |
2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Flynn James E | 0 0.000% |
-1,574,000 (Position Closed) |
Filing History |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
BLACKROCK INC BLK |
1,568,355 5.400% |
1,568,355 (New Position) |
Filing History |
| 2020-06-29 5:22 pm Unchanged |
2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Cormorant Asset Management LP | 1,350,000 5.230% |
0 (Unchanged) |
Filing History |
| 2020-06-29 5:22 pm Purchase |
2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Cormorant Asset Management LP | 1,350,000 5.230% |
1,350,000 (New Position) |
Filing History |
| 2020-06-24 5:03 pm Purchase |
2020-06-19 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 5,424,009 20.800% |
1,428,570 (+35.76%) |
Filing History |
| 2020-06-19 12:10 pm Purchase |
2020-06-19 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Flynn James E | 1,574,000 6.090% |
1,574,000 (New Position) |
Filing History |